Semaglutide: What the Research Shows About One of the Most Studied GLP-1 Peptides

What is semaglutide?

Semaglutide is a long-acting analogue of human GLP-1 (glucagon-like peptide-1) — a hormone involved in regulating blood glucose, appetite and energy balance. The molecule is modified to act far longer than natural GLP-1, enabling long-acting pharmaceutical forms. Semaglutide differs from many experimental peptides in having passed large-scale clinical trials and being used in approved medicinal products — in the US it is marketed as Wegovy, Ozempic and Rybelsus, with different indications and forms.

How does semaglutide act?

Semaglutide binds the GLP-1 receptor, expressed in various tissues including the pancreas and the central nervous system. The main physiological effects include:

• increased glucose-dependent insulin secretion;
• suppression of glucagon secretion when blood glucose is elevated;
• slowed gastric emptying;
• influence on appetite and satiety centres;
• reduced energy intake.

This makes GLP-1 receptor activation interesting for both metabolic control and body-weight management.

Semaglutide and weight reduction

One of the most significant clinical studies is STEP 1, published in the New England Journal of Medicine, in adults with overweight or obesity and no diabetes. Semaglutide combined with lifestyle changes produced significant weight reduction versus placebo — a mean of roughly 15% at 68 weeks, making semaglutide one of the most effective pharmacological approaches to weight reduction studied to date. It must be stressed that these results come from a controlled trial with a specific pharmaceutical form, dosing and medical supervision — they cannot automatically be transferred to any product sold as “semaglutide”.

Semaglutide and the cardiovascular system

One of the most important findings comes from the large SELECT trial: 17,604 patients with established cardiovascular disease and overweight or obesity, without diabetes. Over roughly 40 months of follow-up, a major cardiovascular event occurred in 6.5% of patients on semaglutide versus 8.0% on placebo — a hazard ratio of 0.80, about a 20% relative risk reduction for the composite endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. This matters because it shows semaglutide's effects are not limited to weight change.

Semaglutide and insulin sensitivity

GLP-1 receptor activation ties directly into glucose regulation: GLP-1 receptor → more glucose-dependent insulin → less glucagon → better glycaemic control. The insulin effect is largely glucose-dependent — different from stimulating insulin secretion regardless of glucose concentration. This is one reason GLP-1 receptor agonists hold an important place in modern type 2 diabetes therapy.

Semaglutide and appetite

A substantial share of the weight effect is linked to the central nervous system. Activating GLP-1 receptors in brain structures that regulate feeding behaviour can increase satiety, reduce hunger and the desire to eat, and influence food preferences. The weight reduction is not explained by slowed gastric emptying alone.

Other clinically studied effects

Semaglutide has been studied across cardiometabolic conditions. A trial in patients with heart failure with preserved ejection fraction and obesity enrolled 529 participants and showed improvement both in body weight and in a symptoms-and-physical-limitations score measured by the KCCQ. These results add to the evidence for the broad influence of GLP-1 receptor activation on metabolic and functional state.

Safety and adverse reactions

As with other GLP-1 receptor agonists, the most commonly observed adverse reactions are gastrointestinal: nausea, vomiting, diarrhoea, constipation, abdominal complaints, reduced appetite. In some patients these are serious enough to stop treatment. The official prescribing information for semaglutide products includes warnings about acute pancreatitis, gallbladder disease, severe gastrointestinal reactions and acute kidney injury from dehydration, among other warnings and contraindications. Semaglutide should therefore be seen not as a simple “weight-loss peptide” but as a pharmacologically active molecule with well-established systemic effects.

An important distinction: semaglutide is not every product labelled semaglutide

Products labelled “semaglutide research peptide” exist on the market. The scientific results from clinical trials, however, concern specifically characterised medicinal products manufactured under controlled conditions. It cannot be assumed that a product labelled “Semaglutide 5 mg” shares the purity, sterility, stability, biological activity and manufacturing consistency of an approved pharmaceutical form. This distinction is essential to interpreting semaglutide science correctly.

What the evidence shows

• GLP-1 receptor activation — well established;
• Blood glucose control — strong clinical evidence;
• Weight reduction — strong clinical evidence;
• Appetite reduction — well supported;
• Cardiovascular effects — strong clinical evidence;
• Data in obesity and type 2 diabetes — very large clinical base;
• Status — approved pharmaceutical forms;
• “Research peptide” products — must not be equated with approved medicines.

Conclusion

Semaglutide is a long-acting GLP-1 receptor agonist and one of the best-studied peptide medicines in modern metabolic medicine. Unlike many experimental peptides, it rests on a clinical evidence base spanning tens of thousands of patients: STEP 1 demonstrated significant weight reduction, and SELECT showed roughly a 20% relative reduction in major cardiovascular events in a defined high-risk population. At the same time, semaglutide is a pharmacologically active medicine with potential adverse reactions and contraindications. Its scientific results belong to specific pharmaceutical forms and medical use — they do not transfer automatically to unapproved “research peptide” products.

1. 1.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002.
2. 2.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232.
3. 3.Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF). N Engl J Med. 2023;389(12):1069–1084.
4. 4.Semaglutide — U.S. Prescribing Information. U.S. Food and Drug Administration.